Open AccessEfficacy of cannabinoids in fibromyalgia: a literature review
Author(s) -
Henry Jair Mayorga Anaya,
María Paula Torres Ortiz,
Daniel Hernando Flórez Valencia,
Ómar Fernando Gomezese Ribero
Publication year - 2021
Publication title -
colombian journal of anesthesiology/revista colombiana de anestesiología/revista colombiana de anestesiologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.145
H-Index - 9
eISSN - 2145-4604
pISSN - 0120-3347
DOI - 10.5554/22562087.e980
Subject(s) - fibromyalgia , medicine , cannabis , quality of life (healthcare) , chronic pain , endocannabinoid system , narrative review , etiology , duloxetine , pregabalin , psychiatry , intensive care medicine , alternative medicine , receptor , nursing , pathology
Fibromyalgia is a chronic disease of unclear etiology, involving a neural oversensitization and impaired pain modulation, in addition to a clinical deficiency of the endocannabinoid system. Fibromyalgia is associated with a number of somatic and psychological disorders and hence multiple pharmacological approaches have been used, including opioids, antidepressants, antiepileptics, and more recently medical cannabis. This narrative review comprises a review of the current literature on the efficacy of cannabinoids in fibromyalgia. The studies describe a possible influence of cannabis on pain control in patients with fibromyalgia, with positive effects on quality of life and sleep. The use of cannabis seems to be beneficial in patients with fibromyalgia; however, more robust studies are still needed to establish is actual efficacy in pain management, quality of life and improvement of associated symptoms.